June 6, 2011 (Washington, DC) — A post hoc analysis of a phase 3 clinical trial of the acute migraine drug dihydroergotamine (Levadex, MAP Pharmaceuticals Inc) using 4 different previously published ...

To determine whether a variable definition of biochemical recurrence (BCR) based on clincopathologic features facilitates early identification of patients likely to suffer from disease progression.

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...

Prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer is widely used for reporting the outcome of radical prostatectomy (RP). A standardized BCR definition is lacking ...